Lactobacillus amylovorus LAM1345 isolate, composition including the same and use thereof
AssigneeSynbio Tech Inc.
InventorsSan-Land Young, Hau-Yang Tsen, Chen-Ying Hung, Yu-Cheng Chiang
Life of this patent
Estimating the term…
Abstract
Disclosed herein is an isolated strain of Lactobacillus amylovorus LAM1345, which is deposited at Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH under an accession number DSM 33510. Also disclosed herein are a composition including the isolated strain of Lactobacillus amylovorus LAM1345 for reducing trimethylamine (TMA) and/or trimethylamine-n-oxide (TMAO) levels, and use of the isolated strain of Lactobacillus amylovorus LAM1345 for treating a disease associated with at least an elevated one of TMA and TMAO levels in a subject.
Claims3
A method for treating a disease associated with at least an elevated one of trimethylamine (TMA) and trimethylamine-n-oxide (TMAO) levels, comprising:
- administering, to a subject in need thereof, a pharmaceutical composition consisting of an isolated strain of Lactobacillus amylovorus LAM1345, which is deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH under an accession number DSM 33510;
- and a pharmaceutically acceptable carrier.
A method of reducing a level of trimethylamine (TMA) and/or a level of trimethylamine-n-oxide (TMAO), comprising:
- administering, to a subject in need thereof, a pharmaceutical composition consisting of an isolated strain of Lactobacillus amylovorus LAM1345, which is deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH under an accession number DSM 33510;
- and a pharmaceutically acceptable carrier,
- wherein the isolated strain of Lactobacillus amylovorus LAM1345 is effective for reducing the level of trimethylamine (TMA) and/or a level of trimethylamine-n-oxide (TMAO) in the subject as compared to that of where the isolated strain of Lactobacillus amylovorus LAM1345 is not administered to the subject.
Dependencies are inferred from the claim text.